JCI Editorial Board
potential first-tier conflicts of interest

Updated April 19, 2021

Go to the JCI's conflict-of-interest policy

 

Adaptimmune (M.V. Maus)

Agenus (M.V. Maus)

Allogene (M.V. Maus)

American Gene Technologies (T.M. Dawson)

Amgen (R.G. Weiss)

Arcellx (M.V. Maus)

Ardelyx (M. Donowitz)

Armis Biopharma (W. Nelson)

Arrowhead Pharmaceuticals (A.S. Sodhi)

AstraZeneca (M.J. Kaplan, M.V. Maus, J. Schneck)

Bayer (M.V. Maus)

Biogen (P.A. Calabresi)

Brahm Astra Therapeutics (W. Nelson)

Bristol Myers Squibb (A.P. Feinberg, E.M. Jaffee, M.J. Kaplan, M.V. Maus)

Bristol Myers Squibb/Celgene (W. Nelson)

Cabaletta Bio (M.V. Maus)

Cellectis (M.V. Maus)

Century Therapeutics (M.V. Maus)

Cepheid (A.M. De Marzo, W. Nelson)

CRISPR Therapeutics (M.V. Maus)

CStone Pharmaceuticals (E.M. Jaffee)

Curis Inc. (W.R. Bishai)

D & D Pharmatech (T.M. Dawson)

Digital Harmonic (W. Nelson)

Disarm Therapeutics (P.A. Calabresi)

Dragonfly (E.M. Jaffee)

ESSA Pharma Inc. (W.R. Bishai)

Expansion Therapeutics (J.D. Rothstein)

Genentech (L. Luznik)

Genocea (E.M. Jaffee)

Gilead Sciences Inc. (J.P. Raufman)

GlaxoSmithKline (M.V. Maus, J.D. Rothstein)

HIF Therapeutics (A.S. Sodhi)

Ichnos Sciences (M.V. Maus)

Incysus Therapeutics (M.V. Maus)

Inhibikase Therapeutics Inc. (T.M. Dawson)

Innovakine Therapeutics (M.V. Maus)

Insmed (W.R. Bishai)

Intellia Therapeutics (M.V. Maus)

Ionis Pharmaceuticals (S.I. Taylor)

Janssen Research & Development (A.M. De Marzo)

Johnson & Johnson (A.P. Feinberg)

Kite Pharma (M.V. Maus)

Lilly (B.H. Park)

Lustgarten Foundation (E.M. Jaffee)

MicroMedicine (M.V. Maus)

Mitokinin (T.M. Dawson)

Neuraly (T.M. Dawson)

NexImmune (J. Schneck)

Novartis (C.J. Lowenstein, M.V. Maus)

OncoSTING LLC (W.R. Bishai)

Pfizer (B.H. Park, R.G. Weiss)

Procter & Gamble (A.P. Feinberg, J.P. Raufman)

Roche (M.R. Horton, C. Sumner)

Servier (M.V. Maus)

Sonoval LLC (W.R. Bishai)

TCR2 (M.V. Maus)

Thermo Fisher Scientific (A.P. Feinberg)

Tmunity Therapeutics (M.V. Maus)

Torque (M.V. Maus)

Valted Seq (T.M. Dawson)

Viking Therapeutics (W.R. Bishai)

WindMIL Therapeutics (L. Luznik, M.V. Maus)